Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Immunitas Therapeutics is raising $57,660,258.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jeffrey Goldberg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Immunitas Therapeutics
Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.

To learn more about Immunitas Therapeutics, visit http://www.immunitastx.com/

Contact:
Jeffrey Goldberg, President and Chief Executive Officer
781-810-9292
jgoldberg@immunitastx.com
https://www.linkedin.com/in/jeff-goldberg-43b231/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved